Hepatitis B Diagnostic Test Market Revenue and Value Chain 2016-2026 FMI | Page 3

Report
Description
Report Description
Hepatitis B is an infectious disease associated with the inflammation of the liver. Hepatitis B
infection is caused due to the Hepatitis B virus (HBV) transmitted from one person to other
through infectious blood, semen and other body fluids. Hepatitis B infection can be acute and it
may develop into chronic infection if not diagnosed and treated at an early stage. Chronically
infected Hepatitis B patients eventually develop liver cirrhosis, hepatocellular carcinoma (liver
cancer), fulminant hepatitis B (autoimmune disorder) or suffer from liver failure requiring liver
transplant and can even result in death. In 2014, out of the 360 Mn people infected with
hepatitis B worldwide, around 1 Mn people died of the disease or other complications
associated with it. However, there is a significant decrease in incidence of hepatitis B after
introduction of hepatitis B vaccine. Diagnosis of HBV is achieved by performing several tests for
serological markers of HBV such as HBsAg, anti-HBs antibodies, HBeAg, anti-HBe antibodies and
anti-HBV core antibodies. Currently, nucleic acid testing for HBV DNA is used to detect the
hepatitis B viral load. The diagnosis of hepatitis B involves collection of blood samples followed
by the detection of viral antigens and antibodies in either serum or plasma.
Hepatitis B Diagnostic Test Market: Drivers and Restraints
In vitro diagnostics is the vital market for the hepatitis B diagnostic test as the serological
markers from blood are tested outside the body in the laboratory. Increasing prevalence and
incidence of hepatitis B worldwide and multitude of available tests are the major drivers for the
increasing growth of global hepatitis B diagnostic test market.